PLIANT THERAPEUTICS, INC.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
PLRX$0.79-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity (Unaudited)
Condensed Statements of Stockholders’ Equity
| AdditionalPaid-InCapital · AccumulatedOtherComprehensive Loss · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Common Stock | ||||||
| Shares · Amount | ||||||
| Balance at December 31, 2025 | 61,449,290 | $6 | $1,040,610 | $(15) | $(859,396) | $181,205 |
| Issuance of common stock under benefit plans | 465,279 | — | 74 | — | — | 74 |
| Stock-based compensation expense | — | — | 4,254 | — | — | 4,254 |
| Net unrealized loss on short-term investments | — | — | — | (326) | — | (326) |
| Net loss | — | — | — | — | (20,040) | (20,040) |
| Balance at March 31, 2026 | 61,914,569 | $6 | $1,044,937 | $(341) | $(879,436) | $165,166 |
| Issuance of common stock under benefit plans | 5,585 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 4,187 | — | — | 4,187 |
| Net unrealized loss on short-term investments | — | — | — | (56) | — | (56) |
| Net loss | — | — | — | — | (22,371) | (22,371) |
| Balance at June 30, 2026 | 61,920,154 | $6 | $1,049,124 | $(397) | $(901,807) | $146,926 |
Condensed Statements of Stockholders’ Equity
| AdditionalPaid-InCapital · AccumulatedOtherComprehensive Gain/(Loss) · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Common Stock | ||||||
| Shares · Amount | ||||||
| Balance at December 31, 2024 | 60,860,838 | $6 | $1,013,806 | $321 | $(710,052) | $304,081 |
| Issuance of common stock under benefit plans | 525,345 | — | 498 | — | — | 498 |
| Stock-based compensation expense | — | — | 8,913 | — | — | 8,913 |
| Net unrealized loss on short-term investments | — | — | — | (162) | — | (162) |
| Net loss | — | — | — | — | (56,166) | (56,166) |
| Balance at March 31, 2025 | 61,386,183 | $6 | $1,023,217 | $159 | $(766,218) | $257,164 |
| Issuance of common stock under benefit plans | — | — | — | — | — | $— |
| Stock-based compensation expense | — | — | 6,378 | — | — | $6,378 |
| Net unrealized loss on short-term investments | — | — | — | (160) | — | $(160) |
| Net loss | — | — | — | — | (43,300) | $(43,300) |
| Balance at June 30, 2025 | 61,386,183 | 6 | $1,029,595 | $(1) | $(809,518) | $220,082 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.